Geelong, Australia – Prevatex Pty Ltd an emerging life sciences company focussed on developing and bringing to market next generation probiotics to restore and maintain a healthy maternal microbiome during pregnancy, is pleased to announce that it has in-licensed a suite of intellectual property from the Barwon Infant Study (BIS).

BIS is a major birth cohort study being conducted by the Child Health Research Unit (CHRU) at Barwon Health in collaboration with the Murdoch Children’s Research Institute (MCRI) and Deakin University.

“We are delighted to have completed this in-licensing of core intellectual property from the Barwon Infant Study which shows the clear advantages of the presence of Prevotella copri in the maternal microbiome for a range of important infant outcomes associated with allergies and behaviour” said Dr Greg Collier, PhD, Executive Chairman of Prevatex.

“Prevatex will be guided by the learnings of the Gemini Biotechnology team, which successfully guided Evolve Biosystems, a spin-out from the University of California, Davis, through pre-commercial development.”